Blog
RSS FeedPosted by Michael Wonder on 27 Jul 2016
CADTH calls for patient input on submission from Pierre Fabre for Hemangiol (propranolol hydrochloride)
27 July 2016 - CADTH has received notice of a pending submission from Pierre Fabre for Hemangiol (propranolol hydrochloride). ...
Posted by Michael Wonder on 27 Jul 2016
Vertex seeks deal after NICE rejects CF drug Orkambi
27 July 2016 - NICE has rejected Vertex’s cystic fibrosis drug, Orkambi (lumacaftor+ivacaftor) for routine funding on the National Health Service ...
Posted by Michael Wonder on 27 Jul 2016
Shire and BMS secure NICE recommendations for oncology drugs
27 July 2016 - NICE has issued final guidance recommending Shire’s Oncaspar (pegaspargase) and Bristol-Myers Squibb’s Opdivo (nivolumab) plus Yervoy (ipilimumab) ...
Posted by Michael Wonder on 27 Jul 2016
NICE publishes final guidance on the use of nivolumab in combination with ipilimumab for treating advanced melanoma
27 July 2016 - NICE publishes further guidance on the use of nivolumab (Opdivo) in patients wth melanoma. ...
Posted by Michael Wonder on 27 Jul 2016
Ensuring Australians get most from community pharmacy
27 July 2016 - The Australian Government is ensuring Australians get the best experience possible from community pharmacy and wants to ...
Posted by Michael Wonder on 27 Jul 2016
Review process is an opportunity for pharmacy
27 July 2016 - The release of the discussion paper of the Review of Pharmacy Remuneration and Regulation is an important ...
Posted by Michael Wonder on 27 Jul 2016
Review of pharmacy remuneration and regulation - release of discussion paper
27 July 2016 - The Chair of the Review Panel, Professor Stephen King has announced the release of the review's discussion ...
Posted by Michael Wonder on 26 Jul 2016
CADTH recommends reimbursement of Sunvepra
20 July 2016 - CADTH has recommended that asunaprevir (Sunvepra) be reimbursed in Canada. ...
Posted by Michael Wonder on 26 Jul 2016
Are you paying the NHS for more drugs than you need? Billions worth of life-saving cancer remedies are poured down the drain every year
26 July 2016 - Out of the £5,000 her family paid for medication, a fifth went down the drain. ...
Posted by Michael Wonder on 25 Jul 2016
Praluent recommended for reimbursement by CADTH
20 July 2016 - CADTH has recommended that alirocumab (Praluent) be reimbursed in Canada. ...
Posted by Michael Wonder on 25 Jul 2016
NICE approves Servier’s Lonsurf as third-line cancer therapy
25 July 2016 - The National Institute for Health and Care Excellence has recommended trifluridine/tipiracil as an option for treating metastatic ...
Posted by Michael Wonder on 24 Jul 2016
Cancer experts write to government to demand life saving drug be used on NHS
24 July 2016 - Cancer specialists from around the UK have written to the Government’s health watchdog to demand a potentially ...
Posted by Michael Wonder on 21 Jul 2016
pERC issues final recommendation for Imbruvica (ibrutinib)
19 July 2016 - Canada's pCODR Expert Review Committee has issued a final recommendation for Janssen's ibrutinib for patients with ...
Posted by Michael Wonder on 21 Jul 2016
Lilly’s Alimta wins NICE support
21 July 2016 - NHS use of Eli Lilly's Alimta to treat patients with lung cancer has been endorsed in final ...
Posted by Michael Wonder on 20 Jul 2016
Breakthrough lung cancer drug must be available on NHS, AstraZeneca says
20 July 2016 - A breakthrough lung cancer drug developed by UK scientists, which passed final clinical trials this week, might ...